Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Receivables (2021 - 2025)

Keros Therapeutics (KROS) has disclosed Change in Receivables for 5 consecutive years, with $75000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 96.81% year-over-year to $75000.0, compared with a TTM value of $825000.0 through Dec 2025, down 68.26%, and an annual FY2025 reading of $825000.0, down 68.26% over the prior year.
  • Change in Receivables was $75000.0 for Q4 2025 at Keros Therapeutics, up from -$12.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $18.0 million in Q4 2021 and bottomed at -$18.0 million in Q1 2022.
  • Average Change in Receivables over 5 years is $274384.6, with a median of $83000.0 recorded in 2024.
  • Peak annual rise in Change in Receivables hit 17428.92% in 2025, while the deepest fall reached 3309.38% in 2025.
  • Year by year, Change in Receivables stood at $18.0 million in 2021, then tumbled by 200.0% to -$18.0 million in 2022, then surged by 100.79% to $143000.0 in 2023, then surged by 1546.15% to $2.4 million in 2024, then tumbled by 96.81% to $75000.0 in 2025.
  • Business Quant data shows Change in Receivables for KROS at $75000.0 in Q4 2025, -$12.3 million in Q3 2025, and -$1.5 million in Q2 2025.